TOVX - Synthetic Biologics P/S Multiple

Brandmark of Theriva Corp (TOVX)

P/S multiple fluctuations on the GURU.Markets platform demonstrate that Theriva Biologics, Inc. (TOVX) quotes remain independent of macroeconomics, as the company's success relies on the progress of adenoviral drug trials. High patent margins ensure scalability, while asset value depends on patient survival rates and technology protection. The value of 21.20 indicates the current level of the business's market valuation.

TOVX (Synthetic Biologics) Price-to-Revenue Ratio history from 05/08/2026 to 11/18/2026

Synthetic Biologics (TOVX) - metric breakdowns and financial figures

- market price and analyst price targets:
General company analysis:Theriva Biologics, TOVX
Manufactured product of Theriva Biologics Inc

Investors assess the operational strength of assets through the price-to-sales ratio, where low values signal undervaluation and inflated figures indicate speculative risk. By analyzing changes in the P/S multiple, one can correlate the business value of Theriva Biologics, Inc. (TOVX) with the efficiency of its academic R&D approach and the costs of PhD specialists, thereby determining the company's fundamental stability.